Alterations in 1,25-dihydroxyvitamin D3 structure that produce profound changes in in vivo activity

Vitamin D

Volumn , Issue , 2011, Pages 1429-1435

  DeLuca, Hector F ^a   Plum, Lori A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865308730     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10074-5     Document Type: Chapter

References (67)

1. DeLuca H.F., Schnoes H.K. Vitamin D: recent advances. Ann. Rev. Biochem. 1983, 52:411-439.
2. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16:200-257.
3. Calverley M.J., Jones G. Vitamin D. Antitumor Steroids 1992, 193-270. Academic Press, San Diego. R.T. Blickenstaff (Ed.).
4. Jones G. Analog metabolism. Vitamin D. 1997, 973-994. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
5. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Molec. Cell 2000, 5:173-179.
6. 3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 2004, 43:4101-4110.
7. Binderup L., Binderup E., Godtfredsen W.O. Development of new vitamin D analogs. Vitamin D 1997, 1027-1043. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
8. Jones G. Analog metabolism. Vitamin D 2005, Volume 2:1423-1448. Elsevier Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
9. Plum L.A., Prahl J.M., Ma X., Sicinski R.R., Gowlugari S., Clagett-Dame M., et al. Biologically active non-calcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc. Natl. Acad. Sci. USA 2004, 101:6900-6904.
10. Binderup L., Binderup E., Godtfresen W.O., Kissmeyer M. Development of new vitamin D analogs. Vitamin D 2005, Volume 2:1423-1448. Elsevier Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
11. Colston K.W., Chander S.K., Mackay A.G., Coombes R.C. Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 1992, 44:693-702.
12. James S.Y., Mercer E., Brady M., Binderup L., Colston K.W. EB 1089, a synthetic analog of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 1998, 125:953-962.
13. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S.H., Block N.L., et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol. Biomark. Prev. 1999, 8:241-248.
14. Calverley M.J. Synthesis of MC 903, a biologically active vitamin D metabolite. Tetrahedron. 1987, 43:4609-4619.
15. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem. Pharmacol. 1988, 37:889-895.
16. 3 analogues in dermatology. Dermatology 1995, 2:198-203.
17. Jones G., Calverley M.J. A dialogue on analogs; newer vitamin D drugs for use in bone disease, psoriasis, and cancer. Trends Endocrinol. Metab. 1993, 4:297-303.
18. 3. Biochem. Pharmacol. 1991, 41:1601-1606.
19. Sicinska W., Westler W.M., DeLuca H.F. NMR assignments of tryptophan residue in Apo and Holo LBD-rVDR. Proteins 2005, 61:461-467.
20. 3, a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron. Lett. 1990, 31:1823-1824.
21. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. 1995, 26:852-860.
22. Sprague S.M., Lerma E., McCormmick D., Abraham M., Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am. J. Kidney. Dis. 2001, 48(Suppl. 5):S51-S56.
23. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with pericalcitrol or calcitriol therapy. N. Eng. J. Med. 2003, 349:446-455.
24. Thadhani R., Wolf M. Vitamin D in patients with kidney disease: cautiously optimistic. Adv. Chroni. Kidney Dis. 2007, 14:22-26.
25. Sicinski R.R., DeLuca H.F. Synthesis of 6,7-diaza-19-norvitamin D compounds. Bioorg. Med. Chem. Lett. 1995, 5:899-904.
26. 3. JCS. Chem. Commun. 1977, 890-892.
27. 3 and method for its preparation. US. Patent. #4,424,161 (filed January 3, 1984) 1984.
28. 3: a vitamin D3 analog more active on bone-calcium mobilization than intestinal-calcium transport. Biochemistry 1979, 18:1641-1646.
29. DeLuca H.F., Prahl J.M., Plum L.A. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch. Biochem. Biophys. 2010, in press.
30. 3: an inert vitamin D analog. Arch. Biochem. Biophys. 1981, 209:579-583.
31. DeLuca H.F., Paaren H.E., Schnoes H.K. Vitamin D and calcium metabolism. Topics in Current Chemistry 1979, 1-65. Springer-Verlag, Heidelberg. F.L. Boschke (Ed.).
32. 3. Science 1974, 186:939-941.
33. 3 with the 1-hydroxy group fixed in the axial position lacks biological activity in vitro. J. Steroid Biochem. Mol. Biol. 2007, 103:293-297.
34. 3 analogs with a frozen A-ring conformation. J. Steroid Biochem. Mol. Biol. 2010, 121:46-50.
35. 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl and 2-methylene analogs. J. Med. Chem. 1998, 41:4662-4674.
36. 3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA. 2002, 99:13487-13491.
37. 3 analogues. Bioorg. Med. Chem. Lett. 2000, 10:1129-1132.
38. 3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. J. Med. Chem. 2006, 49:2909-2920.
39. Kubodera N. Development of OCT and ED-71. Vitamin D, volume 2 2005, 1525-1541. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
40. 2, the lead representative of a new class of des-CD analog of cholecalciferol. Bioorg. Chem. 1995, 23:22-32.
41. De Clercq P.J., De Buysser F., Minne G., Schepens W., Vrielynck F., Van Haver D., et al. The development of CD-ring modified analogs of 1α,25-dihydroxyvitamin D. J. Steroid. Biochem. Mol. Biol. 2007, 103:206-212.
42. 3 (2MD): synthesis and biological activity. Bioorg. Med. Chem. 2009, 17:1747-1763.
43. DeLuca H.F., Clagett-Dame M., Plum L.A., Sicinski R.R., Plonska-Ocypa K., Grzywacz P., et al. 13,13-Dimethyl- des-C,D analogs of 1α,25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms and methods of treating skin conditions there of US Utility Patent, Serial No. 12/357702 (filed 1/22/09) 2009.
44. 3. Chem. Biol. 1999, 6:265-275.
45. Ma Y., Khalifa B., Yee Y.K., Lu J., Memezawa A., Savkur R.S., et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest. 2006, 116:892-904.
46. De Clercq P.J., Murad I., Gao L.J., Chen Y.J., Van Haver D., Vandewalle M., et al. Biological activity and conformational analysis of C20 and C14 epimers of CD-ring modified trans-decalin 1α,25-dihydroxyvitamin D analogs. J. Steroid Biochem. Mol. Biol. 2004, 89-90:61-66.
47. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res. 2000, 60:2673-2679.
48. 3. J. Med. Chem. 1995, 39:4497-4506.
49. Ostrem V.K., Lau W.F., Lee S.H., Perlman K., Prahl J., Schnoes H.K., et al. Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs. J. Biol. Chem. 1987, 262:14164-14171.
50. DeLuca H.F., Schnoes H.K., Lau W.F. Seco-sterol compounds effective in inducing cell differentiation. U.S. Patent. #4,940,700 1990.
51. Plum L.A., Prahl J.M., Ma X., Sicinski R.R., Gowlugari S., Clagett-Dame, et al. Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc. Natl. Acad. Sci. USA 2004, 101:6900-6904.
52. Nieves N.J., Ahrens J.M., Plum L.A., DeLuca H.F., Clagett-Dame M. Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. J. Invest. Dermatol. 2010, 130:2359-2367.
53. Slatopolsky E., Finch J.L., Brown A.J., Ritter C.S., Mizobuchi M., Plum L.A., et al. Effect of 2-methylene-19-nor-(20S)-1α-hydro-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism. J. Bone Miner. Res. 2007, 22:686-694.
54. 3 (2MD) reduces potency but allows bone selectivity. Arch. Biochem. Biophys. 2007, 460:274-284.
55. 2 analogs that differ markedly in biological activity in vivo. J. Biol. Chem. 1994, 269:24014-24019.
56. 3 and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20. J. Med. Chem. 2000, 43:4247-4265.
57. 3. Biochem. Pharmacol. 1995, 49:621-624.
58. Ke H.Z., Qi H., Crawford D.T., Simmons H.A., Xu G., Li M., et al. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 2005, 20:1742-1755.
59. Plum L.A., Fitzpatrick L.A., Ma X., Binkley N.C., Zella J.B., Clagett-Dame, et al. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporosis. Int. 2006, 17:704-715.
60. DeLuca H.F., Bedale W., Binkley N., Gallagher J.C., Bolognese M., Peacock M., et al. The vitamin D analog 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year, phase 2, double-blind, placebo-controlled, randomized clinical trial. J. Bone Miner. Res. 2010, [Epub ahead of print].
61. 3 show cell-specific actions. Chem. Biol. 2000, 7:885-894.
62. DeLuca H.F., Barycki R., Rivera-Bermudez M.A., Plum L.A., Clagett-Dame M. Vitamin. D. receptor. antagonists. and. their. use. in. treating. asthma. US. Patent. #2005/0182033 A.1 (Pub. Date.: August. 18, 2005) 2005.
63. Nijenhuis T., van der Eerden B.C.J., Zügel U., Steinmeyer A., Weinans H., Hoenderop J.G.J., et al. The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist. FASEB. J. 2006, 20:E1589-E1598.
64. 3 compounds of superagonistic activity: syntheses, biological activities and interaction with the receptor. J. Med. Chem. 2007, 50:932-939.
65. 3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch. Biochem. Biophys. 2007, 460:161-165.
66. 3 (2MD) selectively eliminates one calcium mobilization activity. Bioorg. Med. Chem. 2009, 17:7658-7669. (2009).
67. 3 markedly reduces in vivo calcemic activity without altering in vitro VDR binding, HL-60 cell differentiation, and transcription. J. Med. Chem. 2010, [Epub ahead of print].